Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P60763
UPID:
RAC3_HUMAN
Alternative names:
p21-Rac3
Alternative UPACC:
P60763; O14658; Q5U0M8
Background:
Ras-related C3 botulinum toxin substrate 3, known as p21-Rac3, is a plasma membrane-associated small GTPase. It transitions between active GTP-bound and inactive GDP-bound states, influencing cell morphology by regulating cell spreading and the formation of actin-based protrusions such as lamellipodia and membrane ruffles. This protein is pivotal in promoting cell adhesion and spreading on fibrinogen through a mechanism involving CIB1 and alpha-IIb/beta3 integrin.
Therapeutic significance:
Ras-related C3 botulinum toxin substrate 3 is linked to a neurodevelopmental disorder characterized by global developmental delay, severe intellectual disability, and structural brain anomalies. Understanding the role of this protein could open doors to potential therapeutic strategies for treating such neurodevelopmental disorders.